Under the terms of the settlement the March 2002 agreement is terminated, Hemispherx regains all licensing rights to Ampligen in Spain, Portugal and Andorra, and Hemispherx and Esteve waive all claims for damages.
In March 2002 Hemispherx entered into an agreement with Laboratorios del Dr Esteve (Esteve) for the sale and distribution of Ampligen in the treatment of patients with chronic fatigue syndrome in Spain, Portugal and Andorra.